Winrevair (sotatercept-csrk), compared to placebo, reduced the risk of all-cause death, lung transplantation, and hospitalization.

Main pulmonary artery diameter is a prognostic indicator in patients with pulmonary arterial hypertension without congenital heart disease.

Redux (also called "fen-phen" in combination with phentermine), was sold in the 1990s until it was removed from the market in 1997 after valvular heart damage and pulmonary hypertension were found.

Dexfenfluramine, aka Redux (also called “fen-phen” in combination with phentermine), was sold in the 1990s until it was ...

Merck, known as MSD outside of the United States and Canada, today announced the first presentation of results from the Phase ...

I took the diet drug Redux in the late 1990s. It was pulled off the market due to correlated heart issues. I saw a cardiologist and learned that I had mild to moderate mitral stenosis with ...

Adding sotatercept (Winrevair) to the treatment regimen for pulmonary arterial hypertension (PAH) in high-risk patients ...

Dear K.T.: Dexfenfluramine, aka Redux (also called "fen-phen" in combination with phentermine), was sold in the 1990s until ...

Sotatercept, an activin signaling inhibitor, was associated with improved outcomes in patients with advanced pulmonary ...

Another study testing sotatercept as an early intervention for pulmonary arterial hypertension (PAH) is anticipated to ...

Marc Humbert, M.D., Ph.D., professor of respiratory medicine at Université Paris-Saclay and Inserm, believes that recent ...

In the ZENITH trial, Winrevair was evaluated based on a composite endpoint of all-cause death, lung transplantation or disease-related hospitalization for patients with pulmonary arterial hypertension ...